title: Prospective Clinical Applications of CRF Peptide Antagonists.
abstract: It is noteworthy that thirty three years of efforts in corticotropin releasing factor (CRF) research by academia and the pharmaceutical industry resulted in several thousand papers and patents, yet little progress has been made to identify and market diagnostic or therapeutic CRF peptides and small molecule ligands. We document the potential relevance of CRF peptide antagonists to reinvigorate stress/anxiety affected "anatomy systems" in order to boost their efficacy.
authors.affiliation: The Salk Institute for Biological Studies, The Clayton Foundation Laboratory for Peptide Biology, San Diego, California 92037. United States.
authors.forename: Jean E
authors.initials: JE
authors.lastname: Rivier
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001007:Anxiety / Q000188:drug therapy / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology*; D013312:Stress, Physiological / Q000187:drug effects
chemical_list: D010455:Peptides; D003346:Corticotropin-Releasing Hormone
keywords: CRF antagonists; CRF pharmacology; CRF receptors; CRF1; CRF2; [DPhe12]CRF; astressin; astressin B; astressin2-B; bacteria resistant antibiotics; cancer; human/rat CRF (h/rCRF); immune system; irritable bowel syndrome
  (IBS); ovine CRF (oCRF); α-hel CRF(9–41)